Literature DB >> 20620921

Breast cancer chemoprevention: progress and controversy.

D Lawrence Wickerham1.   

Abstract

The chemoprevention of breast cancer using pharmacologic agents has had substantial clinical success. Randomized clinical trials evaluating selective estrogen-receptor modulators (SERMs) have shown that these agents reduce the incidence of breast cancer by up to 50% in healthy women at increased risk for the development of the disease. SERMs have been of particular value in women with biopsy-proven risk factors, including atypical hyperplasia or lobular carcinoma in situ of the breast. The agents of established value are important options for women today, and efforts are under way to identify additional more effective therapies. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20620921      PMCID： PMC3034655          DOI： 10.1016/j.soc.2010.03.005

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN： 1055-3207            Impact factor:   3.495


  24 in total

Review 1.  Aromatase inhibitors in the treatment and prevention of breast cancer.

Authors:  P E Goss; K Strasser
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

2.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Authors:  Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade; André Robidoux; Richard G Margolese; Joan James; Scott M Lippman; Carolyn D Runowicz; Patricia A Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark
Journal:  JAMA       Date:  2006-06-05       Impact factor: 56.272

3.  Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.

Authors:  S A Narod; J S Brunet; P Ghadirian; M Robson; K Heimdal; S L Neuhausen; D Stoppa-Lyonnet; C Lerman; B Pasini; P de los Rios; B Weber; H Lynch
Journal:  Lancet       Date:  2000-12-02       Impact factor: 79.321

Review 4.  American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.

Authors:  R T Chlebowski; D E Collyar; M R Somerfield; D G Pfister
Journal:  J Clin Oncol       Date:  1999-06       Impact factor: 44.544

5.  The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.

Authors:  S R Cummings; S Eckert; K A Krueger; D Grady; T J Powles; J A Cauley; L Norton; T Nickelsen; N H Bjarnason; M Morrow; M E Lippman; D Black; J E Glusman; A Costa; V C Jordan
Journal:  JAMA       Date:  1999-06-16       Impact factor: 56.272

6.  Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.

Authors:  Trevor J Powles; Sue Ashley; Alwynne Tidy; Ian E Smith; Mitch Dowsett
Journal:  J Natl Cancer Inst       Date:  2007-02-21       Impact factor: 13.506

7.  Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.

Authors:  Jack Cuzick; John F Forbes; Ivana Sestak; Simon Cawthorn; Hisham Hamed; Kaija Holli; Anthony Howell
Journal:  J Natl Cancer Inst       Date:  2007-02-21       Impact factor: 13.506

8.  Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.

Authors:  Silvana Martino; Jane A Cauley; Elizabeth Barrett-Connor; Trevor J Powles; John Mershon; Damon Disch; Roberta J Secrest; Steven R Cummings
Journal:  J Natl Cancer Inst       Date:  2004-12-01       Impact factor: 13.506

9.  American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.

Authors:  Kala Visvanathan; Rowan T Chlebowski; Patricia Hurley; Nananda F Col; Mary Ropka; Deborah Collyar; Monica Morrow; Carolyn Runowicz; Kathleen I Pritchard; Karen Hagerty; Banu Arun; Judy Garber; Victor G Vogel; James L Wade; Powel Brown; Jack Cuzick; Barnett S Kramer; Scott M Lippman
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

10.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702
View more
  2 in total

1.  Curcumin inhibits metastatic progression of breast cancer cell through suppression of urokinase-type plasminogen activator by NF-kappa B signaling pathways.

Authors:  Hong Zong; Feng Wang; Qing-Xia Fan; Liu-Xing Wang
Journal:  Mol Biol Rep       Date:  2011-09-24       Impact factor: 2.316

2.  Damnacanthal is a potent inducer of apoptosis with anticancer activity by stimulating p53 and p21 genes in MCF-7 breast cancer cells.

Authors:  Muhammad Yusran Abdul Aziz; Abdul Rahman Omar; Tamilselvan Subramani; Swee Keong Yeap; Wan Yong Ho; Nor Hadiani Ismail; Syahida Ahmad; Noorjahan Banu Alitheen
Journal:  Oncol Lett       Date:  2014-02-20       Impact factor: 2.967
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.